Financial Report: Amgen 1Q11

Amgen1Q11

1Q Revenues: $3.7 billion (+3%)

1Q Earnings: $1.1 billion (-4%)

Comments: U.S. product sales in the quarter increased 4% to $2.8 billion. International sales were down 1% to $840 million. Aranesp sales were down 7% to $580 million and Epogen sales were down 14% to $535 million, due to decline in demand. Neulasta and Neupogen sales were up 4% to $1.2 billion. Enbrel sales increased 9% to $875 million. Sales of Sensipar / Mimpara were $187 million (+4%). R&D expenses were up 14% to $703 million in the quarter. Sales of Prolia in the quarter were $27 million. U.S. sales of XGEVA were $42 million.